Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > October 23, 2020
Daily News
October 23, 2020
- Novartis Looks to Solidify Presence in Multiple Sclerosis Arena with Mayzent, then Ofatumumab
October 23, 2020
- Chugai Enjoys Higher Earnings in January-September on Hemlibra
October 23, 2020
- Generic Makers Reorganizing Manufacturing Sites; Leveraging Their Strengths to Survive
October 23, 2020
- Fujifilm Taps Carelink as Chinese Partner for Avigan
October 23, 2020
- Daiichi Sankyo Kicks Off PI Study for I/O Therapy DS-1055
October 23, 2020
- AstraZeneca’s Japan COVID-19 Vaccine Trial Ongoing after Death Reported in Brazil
October 23, 2020
- Empower Smarter Decision Making with Big Data
October 23, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…